Overview

A Trial to Determine the Safety, Pharmacokinetics, and Efficacy of OPC-108459 Administered as a Single Intravenous Dose to Patients With Paroxysmal or Persistent Atrial Fibrillation (AF)

Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
To investigate the safety, pharmacokinetics, and efficacy following 30-minute continuous intravenous administration of OPC-108459 at 0.4, 0.8, 1.6, or 2.4 mg/kg or placebo to patients with paroxysmal or persistent atrial fibrillation
Phase:
Phase 1
Details
Lead Sponsor:
Otsuka Pharmaceutical Co., Ltd.